Loading...

Aclaris Therapeutics

DB:8AT
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
8AT
DB
$218M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • Aclaris Therapeutics has significant price volatility in the past 3 months.
8AT Share Price and Events
7 Day Returns
-3.3%
DB:8AT
-2.6%
DE Pharmaceuticals
-0.2%
DE Market
1 Year Returns
-69.9%
DB:8AT
-28.9%
DE Pharmaceuticals
-10.3%
DE Market
8AT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aclaris Therapeutics (8AT) -3.3% 10.7% -22.9% -69.9% - -
DE Pharmaceuticals -2.6% -4.6% -10.2% -28.9% -20.1% 5.5%
DE Market -0.2% -2.4% 4% -10.3% 11.2% 10.8%
1 Year Return vs Industry and Market
  • 8AT underperformed the Pharmaceuticals industry which returned -28.9% over the past year.
  • 8AT underperformed the Market in Germany which returned -10.3% over the past year.
Price Volatility
8AT
Industry
5yr Volatility vs Market

Value

 Is Aclaris Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Aclaris Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €4.973.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aclaris Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aclaris Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:8AT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-3.95
NasdaqGS:ACRS Share Price ** NasdaqGS (2019-05-20) in USD $5.28
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.4x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aclaris Therapeutics.

DB:8AT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ACRS Share Price ÷ EPS (both in USD)

= 5.28 ÷ -3.95

-1.34x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aclaris Therapeutics is loss making, we can't compare its value to the DE Pharmaceuticals industry average.
  • Aclaris Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Aclaris Therapeutics's expected growth come at a high price?
Raw Data
DB:8AT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.34x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
34.6%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.93x
Germany Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aclaris Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aclaris Therapeutics's assets?
Raw Data
DB:8AT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $4.42
NasdaqGS:ACRS Share Price * NasdaqGS (2019-05-20) in USD $5.28
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.3x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.78x
DB:8AT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ACRS Share Price ÷ Book Value per Share (both in USD)

= 5.28 ÷ 4.42

1.2x

* Primary Listing of Aclaris Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aclaris Therapeutics is good value based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Aclaris Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Aclaris Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Aclaris Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aclaris Therapeutics expected to grow at an attractive rate?
  • Aclaris Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Aclaris Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Aclaris Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:8AT Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:8AT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 34.6%
DB:8AT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 48.7%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17.9%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 3.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:8AT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:8AT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 175 28 9 3
2022-12-31 123 -33 -42 3
2021-12-31 70 -62 -99 4
2020-12-31 39 -85 -125 5
2019-12-31 23 -120 -126 5
DB:8AT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 14 -110 -140
2018-12-31 10 -101 -133
2018-09-30 7 -92 -117
2018-06-30 6 -76 -103
2018-03-31 3 -64 -86
2017-12-31 2 -55 -69
2017-09-30 1 -45 -57
2017-06-30 -41 -50
2017-03-31 -40 -48
2016-12-31 -35 -48
2016-09-30 -31 -42
2016-06-30 -31 -42

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aclaris Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Aclaris Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:8AT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Aclaris Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8AT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.12 0.52 -0.29 2.00
2022-12-31 -0.89 -0.23 -1.55 2.00
2021-12-31 -2.01 -1.47 -2.48 3.00
2020-12-31 -2.60 -2.37 -2.81 4.00
2019-12-31 -2.98 -2.88 -3.11 4.00
DB:8AT Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -3.95
2018-12-31 -4.03
2018-09-30 -3.79
2018-06-30 -3.38
2018-03-31 -2.94
2017-12-31 -2.44
2017-09-30 -2.17
2017-06-30 -2.03
2017-03-31 -2.08
2016-12-31 -2.25
2016-09-30 -2.07
2016-06-30 -2.79

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aclaris Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Aclaris Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aclaris Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Aclaris Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aclaris Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aclaris Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Aclaris Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aclaris Therapeutics's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Aclaris Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aclaris Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8AT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 14.01 -140.07 76.17 61.74
2018-12-31 10.09 -132.74 75.65 61.74
2018-09-30 7.42 -117.12 67.93 43.10
2018-06-30 6.48 -102.57 58.10 38.04
2018-03-31 2.80 -86.19 44.94 32.02
2017-12-31 1.68 -68.52 32.60 39.79
2017-09-30 0.68 -57.06 24.90 33.29
2017-06-30 -49.57 20.42 29.58
2017-03-31 -47.60 16.25 31.45
2016-12-31 -48.08 15.09 29.83
2016-09-30 -41.53 12.81 25.25
2016-06-30 -42.49 10.39 27.51
2016-03-31 -32.89 8.04 19.46
2015-12-31 -23.13 5.33 15.05
2015-09-30 -21.46 3.48 14.99
2015-06-30 -12.94 2.81 7.68
2015-03-31 -11.76 2.46 7.07
2014-12-31 -10.57 2.03 6.51
2013-12-31 -6.98 1.77 3.49

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aclaris Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aclaris Therapeutics has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aclaris Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aclaris Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aclaris Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Aclaris Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aclaris Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aclaris Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aclaris Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aclaris Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aclaris Therapeutics Company Filings, last reported 1 month ago.

DB:8AT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 182.25 33.94 136.76
2018-12-31 215.12 30.52 167.97
2018-09-30 146.33 0.59 134.27
2018-06-30 174.20 0.55 164.60
2018-03-31 200.47 0.14 186.98
2017-12-31 225.26 0.14 193.86
2017-09-30 244.26 0.00 227.85
2017-06-30 168.14 0.00 170.50
2017-03-31 160.29 0.00 153.42
2016-12-31 169.49 0.00 137.22
2016-09-30 81.12 0.00 84.04
2016-06-30 90.24 0.00 94.01
2016-03-31 83.21 0.00 85.25
2015-12-31 92.52 0.00 84.87
2015-09-30 40.19 0.00 38.41
2015-06-30 10.80 0.00 9.85
2015-03-31 15.92 0.00 16.13
2014-12-31 15.92 0.00 16.13
2013-12-31 13.84 0.00 13.32
  • Aclaris Therapeutics's level of debt (18.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 18.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aclaris Therapeutics has sufficient cash runway for 1.2 years based on current free cash flow.
  • Aclaris Therapeutics has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 49.7% each year.
X
Financial health checks
We assess Aclaris Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aclaris Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Aclaris Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aclaris Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Aclaris Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aclaris Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aclaris Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:8AT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3.2%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:8AT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aclaris Therapeutics has not reported any payouts.
  • Unable to verify if Aclaris Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aclaris Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aclaris Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Aclaris Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Aclaris Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aclaris Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aclaris Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Aclaris Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Neal Walker
COMPENSATION $4,363,392
AGE 48
TENURE AS CEO 6.8 years
CEO Bio

Dr. Neal S. Walker, D.O., Co-founded Aclaris Therapeutics, Inc. in 2012 and also has been its Chief Executive Officer and President since July 2012. Dr. Walker is also Co-Founding Member and Partner of NeXeption, LLC. Dr. Walker co-founded NeXeption, LLC in August 2012. He is the Co-Founder and Vice Chairman of Ralexar Therapeutics Inc. He Co-founded Octagon Research Solutions, Inc. in 1999. He Co-founded Trigenesis Therapeutics, Inc., where he served as the Chief Medical Officer (acquired by Dr. Reddy's Laboratories Ltd) and Cutix Inc., a commercial dermatology company that markets PreSun , a sunscreen brand acquired from Bristol-Myers Squibb Co. He Co-founded Vicept Therapeutics, Inc. and served as its Chief Executive Officer, President and Director from 2009 to 2012. He has over 16 years of pharmaceutical industry experience in R&D, regulatory affairs and business development. He has many years of business development experience working with large biopharmaceutical companies, start-ups and universities in the identification, acquisition/licensing and financing of novel development stage assets and in-market brands. He is a Board-certified Dermatologist and served as Consultant to number of pharmaceutical companies between July 2011 and July 2012. He served as Medical Consultant of Johnson & Johnson, AstraMerck and AstraZeneca. Additionally, he has served on the Advisory Committee Safety Team for Prescription to OTC switch of Prilosec®. He has also worked with Vanderbilt University's life science fund assisting the venture firm in the identification and due diligence of medically-related technologies and business concepts. He serves as an Executive Chairman of Follica, Inc. He began his pharmaceutical industry career at Johnson and Johnson, Inc. He has been an Executive Director at Aclaris Therapeutics, Inc. since July 2012. He serves as a Director at Sebacia, Inc. and Zoomi, Inc. He has been a Director of Aldeyra Therapeutics, Inc. since June 2013. Dr. Walker is a director of Alderya Therapeutics, Inc. He has been a Director of Pennsylvania Bio since May 2015. Dr. Walker co-founded and led a number of life science companies. He serves as a Director of Dermatology Summit. He serves on Advisory Boards of Specialty Diets, Inc. He served on the Board of Directors for Octagon and the Advisory Board of Flexible Medical Systems. He served as a Director of Octagon Research Solutions, Inc. He served as the Chief Resident of the Dermatology Residency Program at Philadelphia College of Osteopathic Medicine for 2 years. He completed Internship at St. Barnabas Hospital in New York. Dr. Walker received his MBA from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine degree from Philadelphia College of Osteopathic Medicine and a B.A. in Biology from Lehigh University.

CEO Compensation
  • Neal's compensation has increased whilst company is loss making.
  • Neal's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Aclaris Therapeutics management team in years:

6.8
Average Tenure
52
Average Age
  • The average tenure for the Aclaris Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Neal Walker

TITLE
Co-Founder
COMPENSATION
$4M
AGE
48
TENURE
6.8 yrs

Stuart Shanler

TITLE
Co-Founder & Chief Scientific Officer
COMPENSATION
$2M
AGE
57
TENURE
6.8 yrs

David Gordon

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
49
TENURE
1 yrs

Christopher Powala

TITLE
Co-Founder and Chief Regulatory & Development Officer
COMPENSATION
$536K
AGE
59
TENURE
6.8 yrs

Frank Ruffo

TITLE
Co-Founder & CFO
AGE
52
TENURE
6.8 yrs

Kamil Ali-Jackson

TITLE
Co-Founder
COMPENSATION
$3M
AGE
59
TENURE
6.8 yrs

Michael Tung

TITLE
Senior VP of Corporate Strategy/Investor Relations
AGE
44

Sheila Kennedy

TITLE
Vice President of Marketing

Kevin Scott

TITLE
Vice President of Sales
TENURE
3 yrs

Jeff Wayne

TITLE
Interim Head of Commercial
Board of Directors Tenure

Average tenure and age of the Aclaris Therapeutics board of directors in years:

5.3
Average Tenure
52.5
Average Age
  • The tenure for the Aclaris Therapeutics board of directors is about average.
Board of Directors

Steve Tullman

TITLE
Chairman of the Board
COMPENSATION
$100K
AGE
53
TENURE
6.8 yrs

Neal Walker

TITLE
Co-Founder
COMPENSATION
$4M
AGE
48
TENURE
6.8 yrs

Christopher Molineaux

TITLE
Independent Director
COMPENSATION
$158K
AGE
52
TENURE
5.3 yrs

Anand Mehra

TITLE
Independent Director
COMPENSATION
$155K
AGE
42
TENURE
4.7 yrs

Bryan Reasons

TITLE
Director
COMPENSATION
$256K
AGE
51
TENURE
1.1 yrs

Leslie Baumann

TITLE
Member of Advisory Board

Kenneth Beer

TITLE
Member of Advisory Board

Mark Bradshaw

TITLE
Member of Advisory Board
AGE
65

James Leyden

TITLE
Member of Advisory Board
AGE
77

Klaus Theobald

TITLE
Member of Advisory Board
AGE
62
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. May 19 Sell Deerfield Management Company, L.P. Company 09. May 19 10. May 19 -614,710 €5.48 €-3,349,431
23. Oct 18 Buy Sofinnova Investment, Inc. Company 22. Oct 18 22. Oct 18 372,093 €9.38 €3,488,400
X
Management checks
We assess Aclaris Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aclaris Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company’s products under development include ATI-450 MK-2 pathway oral inhibitor for the treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated periodic syndrome, and pyoderma gangrenosum; ATI-1777 JAK1/JAK3 soft topical inhibitor for atopic dermatitis, vitiligo, and alopecia areata; ITK/JAK3 soft topical and oral inhibitors to treat psoriasis and inflammatory diseases; MK-2 pathway oral inhibitor for oncology; and ITK-JAK3 oral gut-restricted inhibitor for ulcerative colitis/Crohn’s disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.

Details
Name: Aclaris Therapeutics, Inc.
8AT
Exchange: DB
Founded: 2012
$195,058,210
41,272,308
Website: http://www.aclaristx.com
Address: Aclaris Therapeutics, Inc.
640 Lee Road,
Suite 200,
Wayne,
Pennsylvania, 19087,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ACRS Common Stock Nasdaq Global Select US USD 07. Oct 2015
DB 8AT Common Stock Deutsche Boerse AG DE EUR 07. Oct 2015
LSE 0H8T Common Stock London Stock Exchange GB USD 07. Oct 2015
Number of employees
Current staff
Staff numbers
169
Aclaris Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 22:46
End of day share price update: 2019/05/20 00:00
Last estimates confirmation: 2019/05/09
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.